Recombinant Secretory Immunoglobulin A in Passive Immunotherapy: Linking Immunology and Biotechnology

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|4|1|51-67

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.4, Iss.1, 2003-02, pp. : 51-67

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dendritic Cells in Tumor Immunology and Immunotherapy

By  

Current Drug Targets, Vol. 5, Iss. 1, 2004-01 ,pp. : 17-39

Bentham Science Publishers

Access to resources Recommend Favorite

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy†

By Madsen Caroline B.   Wandall Hans H.   Pedersen Anders Elm  

Immunopharmacology and Immunotoxicology, Vol. 35, Iss. 6, 2013-12 ,pp. : 649-652

Informa Healthcare

Access to resources Recommend Favorite

The Recombinant T Cell Receptor Strategy: Insights into Structure and Function of Recombinant Immunoreceptors on the Way Towards an Optimal Receptor Design for Cellular Immunotherapy

By  

Current Gene Therapy, Vol. 2, Iss. 2, 2002-05 ,pp. : 211-226

Bentham Science Publishers

Access to resources Recommend Favorite

Chemical Modifications in Aggregates of Recombinant Human Insulin Induced by Metal-Catalyzed Oxidation: Covalent Cross-Linking via Michael Addition to Tyrosine Oxidation Products

By Torosantucci Riccardo  

Pharmaceutical Research, Vol. 29, Iss. 8, 2012-08 ,pp. : 2276-2293

Springer Publishing Company

Access to resources Recommend Favorite

Editorial [Hot Topic:Active and Passive A#946;-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 1, 2009-03 ,pp. : 1-6

Bentham Science Publishers

Access to resources Recommend Favorite